Spectral AI, Inc. Q3'26 Financial Results Conference Call - SPECTRAL AI INC

Financial Performance:

• Research & Development (R&D) revenue for Q3 2026 was $2.9 million, a 24.7% decrease from $3.8 million in Q3 2025, driven by the narrowing scope of the BARDA cost-share phase.
• Revenue from other U.S. government programs (primarily M-TEC Antel) declined to $0.1 million from $0.4 million as the program concluded.
• Gross margin contracted to 27.2% from 42.7% due to the inclusion of Spectral AI's share of BARDA development costs in the Cost of Revenue.
• Total operating expenses decreased 4% to $4.7 million (from $5.0 million), with R&D rising to $2.0 million (due to UK label expansion) and G&A falling to $2.3 million (lower legal fees).
• Selling and marketing expenses increased approximately $50,000 to $0.4 million to support commercial readiness.
• Net loss for the quarter was $3.7 million ($0.11 per share), compared to $3.6 million ($0.13 per share) in the prior year period.
• Adjusted EBITDA loss widened to $3.7 million from $3.1 million, reflecting lower gross profits partially offset by reduced operating expenses.
• Cash position ended the quarter at $11.2 million (down from $15.4 million at year-end 2025); $10.5 million was used in operating activities, offset by $6.3 million in financing activities.
• Avenue credit facility is fully drawn at $15 million, with interest-only payments through March 2027 and maturity in March 2028.

Guidance and Future Outlook:

• Updated 2026 R&D revenue guidance to approximately $13 million (revised down from $18.5 million) due to the completion of the M-TEC program and delayed BARDA reimbursement timing.
• The guidance excludes potential revenue from DeepView AI device sales or new government awards.
• First commercial sales and manufacturing of the initial 30 DeepView AI systems for BARDA-supported deployments are targeted for 2026.
• TNT (Triage and Treatment) study is set to commence at 4-5 centers in early December 2026, with expansion to 12 centers planned by Q1 2027.
• UKCA approval for the improved algorithm/hardware is now expected in early 2027, delaying international sales in the UK, Australia, or GCC until that approval is secured.
• Commercial model focuses on device purchase/lease agreements with minimum three-year terms, pairing recurring software/service revenue with hardware.
• NTAP reimbursement determination by CMS is expected in August 2027, potentially supporting a $2,750 per-patient add-on payment for 2-3 years.

Business Segments and Product Lines:

• DeepView AI System: Commercialization focus shifting from R&D to establishing clinical confidence, economic value demonstration, and clinical workflow integration at U.S. burn centers.
• Manufacturing: Initial production of 30 units for BARDA-supported deployments has commenced.
• Label Expansion: Self-funded UK study initiated to expand device labeling to include head, hand, and foot burns; 10 patients enrolled across 4 centers.
• Reimbursement Strategy: Advancing CPT-3 coding to CPT-1 pathway (supported by TNT study) for physician reimbursement effective January 1, 2027; NTAP application submitted for hospital system reimbursement.
• International: Preparing for post-UKCA sales launch; leveraging existing relationships with global burn centers for initial placements.

Market and Competitive Landscape:

• Strategy aims to move beyond mass casualty preparedness to establish DeepView AI as a standard of care for everyday burn treatment to ensure equitable access regardless of geography or socioeconomic status.
• Market traction evidenced by positive reception at the Southern Regional Burn Conference and American College of Emergency Physicians Scientific Assembly.
• Go-to-market approach is Key Opinion Leader (KOL) driven, targeting leading burn surgeons and trauma center physicians to facilitate procurement processes.
• Competitive differentiation relies on objective, reproducible AI analysis for non-healing burn identification and standardized burn surface area calculation.

Risks and Challenges:

• Regulatory Delays: UKCA approval pushed to early 2027; CMS NTAP determination not until August 2027.
• Reimbursement Uncertainty: Reliance on successful NTAP approval and CPT-1 coding migration to drive adoption; physician-side reimbursement remains unproven.
• Margin Pressure: Gross margins remain depressed by the BARDA cost-share structure until commercial device sales scale.
• Procurement Friction: Navigating complex hospital and burn center procurement processes for new medical technology.
• Forward-Looking Risks: Standard safe harbor risks regarding unproven commercial execution and potential differences between projected and actual financial results.

Management Commentary and Tone:

• Management expressed cautious optimism, emphasizing the successful transition from a research organization to a commercial enterprise.
• Tone reflected discipline in capital deployment and cost management while investing heavily in commercialization and clinical studies.
• Executives highlighted the "extraordinary" nature of the technology's ability to diagnose burn tissue as a key driver for overcoming adoption hurdles.
• CFO confirmed the business is well-capitalized with $11 million in cash and $90 million in accessible BARDA non-dilutive funding.

Analyst Questions and Answers:

• Reimbursement (NTAP): Confirmed application submitted for hospital systems (not primarily physicians); proposed rate of $2,750/patient; resolution expected August 2027 for a 2-3 year term.
• Commercial Deployment: Acknowledged procurement hurdles but noted traction with purchase and lease models (3-year minimum) across both urban and rural centers.
• Conference Feedback: Executives confirmed medical conferences were effective lead generators, allowing for live device demonstrations and expanding awareness among skeptical centers.
• Pricing Strategy: Pricing determined via third-party consulting and KOL input; considered compelling due to operational cost reductions and potential reimbursement pathways.
• Gross Margin Drivers: Explained that current low margins stem from BARDA cost-sharing; anticipated improvement as higher-margin commercial device sales and recurring revenue scale.
• Sales Targets: Focus remains on KOL-driven engagements with burn centers and trauma physicians, utilizing on-site demonstrations to advance procurement.

Other Key Points:

• DeepView AI technology quantifies Total Body Surface Area (BSA) to aid in triage, fluid resuscitation, and treatment decisions.
• The company has 32.2 million shares outstanding as of September 30, 2026.
• A $0.8 million gain from warrant liability fair value changes offset $0.6 million in net interest expense, resulting in net other income of $0.2 million.
• Management reaffirmed commitment to national sales footprint expansion to support consistent, objective burn wound assessments.